​

Cardiff Oncology (CRDF) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CRDF Stock Rating

Cardiff Oncology stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (80.00%), 1 Hold (10.00%), 1 Sell (10.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 1 8 Strong Sell Sell Hold Buy Strong Buy

CRDF Price Target Upside V Benchmarks

TypeNameUpside
StockCardiff Oncology-
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$3.79$3.79$3.79
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2525---7
May, 2525---7
Apr, 2524---6
Mar, 2524---6
Feb, 2523---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 28, 2025H.C. WainwrightBuyBuyhold
Sep 06, 2024Craig-HallumBuyinitialise
Jun 05, 2022Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.92$-0.71$-0.86$-0.93$-0.95----
Avg Forecast$-1.03$-0.66$-0.93$-0.99$-0.99$-0.98$-1.14$-1.39$-1.79
High Forecast$-0.48$-0.31$-0.42$-0.96$-0.93$-0.73$-0.85$-1.22$-0.23
Low Forecast$-1.72$-1.11$-1.48$-1.01$-1.03$-1.37$-1.50$-1.56$-3.33
Surprise %-10.68%7.58%-7.53%-6.06%-4.04%----

Revenue Forecast

$0 $150K $300K $450K $600K $750K Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$365.99K$359.00K$386.00K$488.00K-----
Avg Forecast$267.50K$218.17K$277.25K$358.00K$609.40K$320.00K$150.00K$150.00K$200.00K
High Forecast$406.79K$331.77K$405.23K$375.46K$749.26K$529.84K$248.36K$248.36K$331.15K
Low Forecast$158.28K$129.09K$161.35K$331.80K$499.51K$104.92K$49.18K$49.18K$65.57K
Surprise %36.82%64.55%39.22%36.31%-----

Net Income Forecast

$-150M $-120M $-90M $-60M $-30M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-19.28M$-27.74M$-37.51M$-41.44M$-45.45M----
Avg Forecast$-45.91M$-24.40M$-36.37M$-41.47M$-43.01M$-56.16M$-52.58M$-62.18M$-80.19M
High Forecast$-21.54M$-19.52M$-29.10M$-33.17M$-41.45M$-32.54M$-38.03M$-54.58M$-10.12M
Low Forecast$-76.98M$-29.28M$-43.64M$-49.76M$-45.91M$-61.36M$-67.12M$-69.77M$-148.55M
Surprise %-58.00%13.68%3.12%-0.06%5.70%----

CRDF Forecast FAQ

Is Cardiff Oncology stock a buy?

Cardiff Oncology stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Cardiff Oncology is a favorable investment for most analysts.

What is Cardiff Oncology's price target?

Cardiff Oncology's price target, set by 10 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $3.79.

How does Cardiff Oncology stock forecast compare to its benchmarks?

Cardiff Oncology's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Cardiff Oncology over the past three months?

  • June 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Cardiff Oncology’s EPS forecast?

Cardiff Oncology's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.98, marking a 3.16% increase from the reported $-0.95 in 2024. Estimates for the following years are $-1.14 in 2026, $-1.39 in 2027, and $-1.79 in 2028.

What is Cardiff Oncology’s revenue forecast?

Cardiff Oncology's average annual revenue forecast for its fiscal year ending in December 2025 is $320K, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $150K, followed by $150K for 2027, and $200K for 2028.

What is Cardiff Oncology’s net income forecast?

Cardiff Oncology's net income forecast for the fiscal year ending in December 2025 stands at $-56.165M, representing an 23.56% increase from the reported $-45.455M in 2024. Projections indicate $-52.577M in 2026, $-62.176M in 2027, and $-80.192M in 2028.